<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="761">
  <stage>Registered</stage>
  <submitdate>9/09/2005</submitdate>
  <approvaldate>9/09/2005</approvaldate>
  <nctid>NCT00166257</nctid>
  <trial_identification>
    <studytitle>PC-Trial: Patent Foramen Ovale and Cryptogenic Embolism</studytitle>
    <scientifictitle>Randomized Clinical Trial Comparing the Efficacy of Percutaneous Closure of Patent Foramen Ovale (PFO) With Medical Treatment in Patients With Cryptogenic Embolism</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ICN98008</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Embolism, Paradoxical</healthcondition>
    <healthcondition>Heart Septal Defects, Atrial</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Percutaneous closure of patent foramen ovale
Treatment: drugs - Medical antitrhombotic treatment

Active Comparator: Medical antitrhombotic treatment - 

Experimental: Device Implant - Percutaneous closure of patent foramen ovale


Treatment: devices: Percutaneous closure of patent foramen ovale
Percutaneous implantation of an AMPLATZERÂ® PFO Occluder

Treatment: drugs: Medical antitrhombotic treatment
Investigator's choice: Anticoagulation to INR 2.0 - 3.0 OR Aspirin 100-325 mg/d OR Clopidogrel 75-150 mg/d

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time to death (Fatal stroke, cardiovascular, non-CV),</outcome>
      <timepoint>continuosly</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>non-fatal cerebrovascular event,</outcome>
      <timepoint>continuosly</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>peripheral embolism</outcome>
      <timepoint>continuosly</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>New arrhythmias,</outcome>
      <timepoint>continuosly</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>myocardial infarction</outcome>
      <timepoint>continuosly</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>rehospitalization related to PFO or its treatment</outcome>
      <timepoint>continuosly</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>device problems</outcome>
      <timepoint>continuosly</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>bleeding complications</outcome>
      <timepoint>continuosly</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age below 60 years

          -  Ischemic stroke or peripheral thromboembolism, radiologically verified

          -  Absence of an identifiable cause of embolism

          -  Echocardiographically verified patent foramen ovale

          -  Sufficient recovery from index event to allow independent daily activities</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Any identifiable cause for thromboembolic event other than PFO

          -  Cardiac diseases: mural thrombus, dilated cardiomyopathy, prosthetic heart valve or
             mitral stenosis, endocarditis, atrial fibrillation

          -  Vascular system: significant atherosclerosis or dissection of the aorta, collagen
             vascular disease, arteritis, vasculitis

          -  Pre-existing neurologic disorders or intracranial disease, e.g., multiple sclerosis,
             arteriovenous malformations, previous hemorrhage

          -  Contraindications for antithrombotic or anticoagulant therapy

          -  Patients already on chronic anticoagulant therapy for another disease

          -  Previous surgical or percutaneous PFO-closure

          -  Drug or alcohol abuse

          -  Pregnancy

          -  Septicemia or severe infectious disease

          -  Severe CNS disease

          -  No informed consent

          -  Foreseen difficulties with study compliance, especially the long-term follow-up</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2000</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>414</actualsamplesize>
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/05/2011</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Monash Medical Centre - Melbourne</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <hospital>Alfred Hospital - Prahan</hospital>
    <postcode> - Melbourne</postcode>
    <postcode> - Nedlands</postcode>
    <postcode> - Prahan</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brugge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Bern</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Foundation for Cardiovascular Research, Zurich</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>St. Jude Medical</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to compare two treatments strategies to prevent further attacks
      in patients who have suffered an stroke or occlusion of a major artery with no obvious reason
      other than a persistent small opening between the upper heart chambers</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00166257</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bernhard Meier, MD</name>
      <address>Dept. Cardiology, University Hospital Insel, Berne, Switzerland</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>